Global Innovation Converges as International Industry Resources Integrate: 2026 China Cell & Gene Therapy Congress (CSGCT) Officially Launches

May 09, 2026 15:22 CST Updated 15:22

Cell and Gene Therapy (CGT) is reshaping the boundaries of humanity’s fight against disease. As one of the countries with the most active global CGT R&D pipelines, the richest clinical resources, and the most cutting-edge policy innovations, China is contributing “Chinese solutions” and “Chinese wisdom” to the global development of CGT, leveraging its unique institutional advantages, scientific research capabilities, and industrial ecosystem. It has become an indispensable and vital force in the global CGT innovation ecosystem.

In 2026, China’s regulatory framework for cell and gene therapy (CGT) underwent a systemic overhaul. The “Regulations on the Clinical Research and Clinical Translational Application Management of New Biomedical Technologies” (known in the industry as “Order No. 818”) and the “Implementation Regulations of the Drug Administration Law of the People’s Republic of China” (known in the industry as “Order No. 828”) have been successively implemented, jointly establishing a new regulatory landscape for cell and gene therapy. The concentrated release of policy dividends is accelerating China’s emergence as a key source of global CGT innovative assets.

September 19-20, 2026, the China Society for Gene and Cell Therapy (CSGCT) Conference will be held inBeijing · ZhongguancunNational Independent Innovation Demonstration Zone Exhibition and Trading Center – Conference Center Reopens. As the most internationally influential summit in the field of cell and gene therapy in the Asia-Pacific region,CSGCT andASGCT(Close collaboration with the American Society of Gene & Cell Therapy), leveraging top-tier international resources in the field of CGT, and bringing together outstanding global regulatory agencies, scientists, innovative pharmaceutical companies, clinical experts, supply chain enterprises, large pharmaceutical companies, and investment institutions, this conference will feature1 Main Forum +23High-End Sub-forum, ushering in300+ Top Experts from China and Abroad, 3,000+ Attendees, and 500+ Investment Institutions, delivering the most cutting-edge regulatory and market access information, clinical breakthroughs, scientific research advancements, technologies and applications, high-quality collaborative projects, and matchmaking for domestic and international investment and business development (BD) opportunities in the global cell and gene therapy (CGT) field, thereby building a platform for in-depth exchange and cooperation between China’s cell and gene therapy industry and the global industrial chain.

Conference Basic Information

Conference Name：2026 China Society for Gene and Cell Therapy (CSGCT) Conference
Conference Schedule：September 19-20, 2026 (Saturday-Sunday)
LargeVenue: Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center- Convention Center (Beijing)
Guiding Organization: Beijing Municipal Science and Technology Commission, Zhongguancun Science Park Management Committee, People's Government of Haidian District, Beijing Municipality
Organizer: Zhongguancun Science City Management Committee,CSGCT China Cell and Gene Therapy Alliance
Organizer: Beijing Medical and Health Technology Development Center,HIEA Medical Innovation Ecosystem Alliance,VCBeat

Limited-Time Free Tickets: Scan the QR Code to Claim Now

Conference Framework

The 2026 CSGCT Conference will feature one main forum, 23 sub-forums, one awards ceremony, two roadshows, and five conference events.

Conference Highlights

Internationalization: Global Innovation Forces Converge

The conference brings together the most foundational and influential figures in the global field of cell and gene therapy, with guests includingJude Samulski、Carl June、Frank Graham、Mark Kay、Gao Guangping, Zhang Feng,Terence Flotte、Barry Byrn、Ana Hidalgo-SimonThe founders who defined the industry direction, fromCapstan、Arbor Biotechnologies、Voyager Therapeutics、Eli Lilysenior executives from internationally leading companies, as well as those fromStanford、UNC、UMich、McMaster、HKUauthoritative experts from academic institutions。

Coverage of AttendeesUnited States, EuropeWaitA CGT R&D Hub, with Extensions intoAustralia, Japan, Singaporesuch as the Asia-Pacific innovation hub, and connectIndonesia, Malaysiaand other emerging markets, as well asUnited Arab Emirates, Saudi Arabiaindustrial and capital forces from regions such as these. They come with clear collaborative objectives—to connect with China’s cutting-edge pipelines, clinical resources, and industrialization capabilities, and to explore cross-border business development (BD) and investment opportunities.

The 2026 CSGCT Conference will feature the theme “Gathering Momentum for Symbiotic Growth,”Global“Co-evolution of the CGT Alliance Network”China IIT"New Pivot Point for Global Standards"Southeast Asia"International Innovation and Collaboration in Cell and Gene Therapy" Sub-forum, and "China IIT Resource Matchmaking Meeting”“CGTOverseas BD Resource Matchmaking Session"etc."Special Campaign。

Regulation& Clinical: Authoritative Interpretation and In-Depth Exchange

In 2026, as China’s CGT regulatory framework continues to improve, the CSGCT Conference will fully leverage itsSwingDual Advantages in Pharmaceutical and Biomedical New Technologies, offering attendees:

Authoritative Policy Interpretation: Latest Regulatory Practices,IND/BLA Submission and Accelerated Pathways
Resource Matchmaking Platform: Connecting with China's Top Clinical Research Institutions,PI Resources and Patient Networks
International Collaboration Window: Facilitating Precise Alignment of Overseas Innovation Projects with Chinese Clinical Resources and Regulatory Pathways

Authoritative Regulation and ReviewSpecializedHome LiveInterpretation of the Latest Review Key Points and Submission Strategies.Peking University Third Hospital, Peking University Cancer Hospital, Peking Union Medical College Hospital,Wuhan Union Hospital, Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing Children's Hospital, and PLA General Hospital (301 Hospital)Leading clinical principal investigators (PIs) share the latest clinical trial data, key clinical design concepts, and product selection rationale。

The 2026 CSGCT Conference will feature“Global CGT inCardiovascular and Metabolic FieldsClinical Applications and Breakthroughs” “Global CGT inCNS and OncologyClinical Applications and Breakthroughs” “Global CGT inAnti-Aging and Longevity FieldSub-forum on “Clinical Applications and Breakthroughs,” as well as “Policy Application and Interpretation of Advanced Therapy Medicinal Products and New Clinical Technologies (Closed-Door Meeting）”“China IIT Resource Matchmaking Conference"ChinaGrade 3A HospitalNew Biomedical TechnologiesIn-Depth Study Tour” and other special campaigns.

Full Industry Chain: Key Decision-Makers Convene

Regulatory Authorities, ClinicalPI、Domestic and international large pharmaceutical companies,Innovative pharmaceutical companies, research institutions, supply chain and CXO enterprises, investment firms, and patient organizations have gathered to provide multi-perspective cutting-edge insights and exchanges. Among themExceeding70% are at the decision-maker level, directly reaching the key decision-makers from R&D project initiation and process selection to commercialization advancement.

Full Spectrum: Comprehensive Coverage of Cutting-Edge Technologies

Comprehensive coverage of technological pathways, with sub-forums dedicated to major technical branches including gene therapy, gene editing, immune cell therapy, stem cell therapy, exosomes, induced pluripotent stem cells (iPSCs), in vivo cell therapy, nucleic acid drugs, oncolytic viruses, and tumor vaccines, inviting leading enterprises from each sector to share their industrialization progress. Additionally, sessions are arranged focusing on investment and financing, clinical translation, delivery technologies, and regulatory affairs,Sub-forums on topics of common interest to industries such as CMC and AI enablement.

Precision Outreach: 1-on-1 Targeted Meetings

The conference features a dedicated matchmaking space, complemented by pre-event1-on-1 Targeted Meeting Services help you secure target partners in advance, facilitate efficient on-site matchmaking, and ensure every interaction precisely reaches decision-makers, thereby enabling businesses to establish effective connections with their target audiences. Additionally, the conference allocates ample time for networking within its agenda, featuring high-quality social opportunities such as forum interactions, coffee break networking, closed-door invited luncheons, dinner receptions, and cocktail parties.

Previous Editions Review

Awarded at the 2025 CSGCT ConferenceNearly 60Extensive coverage by leading national media platforms, including Xinhua Net, People's Daily Health Client, Guangming Daily, China Daily, Beijing Daily, Securities Times, 21st Century Business Herald, PharmaCube, and Tongxieyi, has generated widespread dissemination across the entire internet, with a cumulative total of published reportsOver 200 articles, precise coverageOver 400,000Professionals, achieving over3 millionmedia dissemination value.

Conclusion

For Global Cell and Gene Therapy, Look to China; For Chinese Cell and Gene Therapy, Look to CSGCT!

In 2026, China has become a key destination for global cell and gene therapy (CGT) companies to conduct clinical trials and validate their technology platforms. As the core platform connecting China with the global CGT ecosystem, CSGCT provides domestic and international enterprises with one-stop services, including policy interpretation, clinical resource matchmaking, and business development (BD) collaboration.

We cordially invite the globalScientists, clinical experts, entrepreneurs, investors, and industry partners in the field of CGT,September 19-20, 2026, GatheringBeijing, jointly explore frontier issues in the development of CGT, connect global innovation resources, and promote collective progress in the industry.

Limited-Time Free Tickets – Scan the QR Code to Claim Now

2026 CSGCT: See You in Beijing This Golden Autumn!

For conference sponsorship and attendance, please contact Ms. Li at 18600921680 (phone/WeChat) for details.

Guests of Previous CSGCT Conferences

Note: The guests are listed in no particular order.

CSGCT Alliance Activities

2026 ASGCT: Straight to Boston—Clarifying the Logic Behind CGT’s Next Wave of Growth (May 10–16)

About the CSGCT China Cell and Gene Therapy Alliance

Mission and Positioning of the CSGCT Alliance and Conference

Promoting the Application of GCT Technology in China to Alleviate Patient Suffering and Save Lives
To become a platform for scientists, physicians, patient organizations, regulatory agencies, enterprises, and investors in China’s GCT field to convene, and a connector fostering collaboration among them.
Promote the Brand Value of China’s CGT Industry, Accelerate Deep Global Integration, and Enhance Access to Innovative Therapies

Vision of the CSGCT Alliance and Conference

Driving Innovation and Translation: Focusing on the Field of Cell and Gene Therapy (CGT), Bridging the Entire Chain from Basic Research, Technology Development to Clinical Trials and Industrial Translation, Accelerating the Integration of Chinese CGT Products, Technologies, and Services into the Global Market
Building a Collaborative Ecosystem: By integrating domestic and international research resources, clinical institutions, enterprises, and capital, we establish a multi-dimensional collaborative platform encompassing “government, industry, academia, research, healthcare, and finance” to address common industry challenges (such as financing needs, regulatory communication, supply chain stability, and international cooperation).